Biotech · Private company
Biodesix, Inc.
Track this companyFree. Adds Biodesix, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials73 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials7
- A Multicenter, Retrospective, Chart Review Study Evaluating the Impact and Utility of the Blood-Based Proteomic Integrated Classifier and Auto-Antibody Tests in the Real-WorldACTIVE_NOT_RECRUITING · started Sep 19, 2024ClinicalTrials.gov NCT06728319 · fetched Nov 12, 2026
- Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based ChemotherapyTERMINATED · started Feb 1, 2021ClinicalTrials.gov NCT04676386 · fetched Nov 12, 2026
- Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung NodulesACTIVE_NOT_RECRUITING · started Dec 18, 2020ClinicalTrials.gov NCT04171492 · fetched Nov 12, 2026
- Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC ImmunotherapyTERMINATED · started Apr 15, 2019ClinicalTrials.gov NCT03951012 · fetched Nov 12, 2026
- A Registry to Evaluate the Performance of the BDX-XL2 TestCOMPLETED · started Oct 16, 2018ClinicalTrials.gov NCT03766958 · fetched Nov 12, 2026
- Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC SubjectsACTIVE_NOT_RECRUITING · started Apr 4, 2016ClinicalTrials.gov NCT03289780 · fetched Nov 12, 2026
- A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive LabelPHASE2 · TERMINATED · started Nov 1, 2014ClinicalTrials.gov NCT02318368 · fetched Nov 12, 2026